ALPRE Predilife S.A.
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Predilife (EPA: ALPRE)
›
Predilife (EPA: ALPRE) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 20 employees.
The shares were at 0.5000 EUR on 20 November 2026, down 84.1% over 52 weeks. Its 52-week range is 0.4500 EUR to 4.000 EUR: the price is 87.5% below the high and 11.1% above the low.
Its market capitalisation is 1.97M EUR.
Predilife reports return on equity of 56.9%, an operating margin of -390.9% and revenue up 32.1% year over year.
Its debt exceeds its cash by 4.78M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.